Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
Express News | Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at Aasld’s the Liver Meeting 2024
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Cuts Target Price to $6.2
Atea Pharmaceuticals Advances in HCV Treatment Development
Atea Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Express News | Atea Pharmaceuticals Inc Qtrly Shr Loss $0.37